ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$1.12
-0.01 (-0.88%)
▼
5d:
-8.2%
30d:
+12.0%
90d:
-23.81%
HOLD
LOW Confidence
Analysis Updated: Apr 29, 2026 12:00 AM ET
Earnings: May 08, 2026
8d
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $1.12, which is considered fair relative to its 30-day fair value range of $1.08 to $1.23.
Technical Outlook: Technically, ENTX is in a strong downtrend. The price is currently testing key support at $1.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ENTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.00 (+696.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENTX is in a strong downtrend. The price is currently testing key support at $1.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ENTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.00 (+696.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.08 -
$1.23
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 696.5% below Wall St target ($9.00)
- CAUTION: Recommendation downgraded due to -8.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.23
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.28
(25.2%)
Support & Resistance Levels
Support Level
$1.11
Resistance Level
$1.36
Current Trend
Strong Downtrend
Technical data as of
Apr 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.98
Wall Street Target
$9.00
(+696.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 29, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Geno J Germano
BUY
20000 shares
2026-03-09
Sean Ellis
BUY
10000 shares
2026-03-05
Sean Ellis
BUY
18000 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$878 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$226 | 60 HOLD |
